Cyprus Mail
EuropeWorld

Denmark ditches J&J COVID-19 shots from vaccination programme

file photo: empty vials of johnson & johnson's coronavirus disease (covid 19) vaccine are seen on a table at a vaccination centre in ronda

Denmark became the first country to exclude Johnson & Johnson’s COVID-19 shots from its vaccination programme over a potential link to a rare but serious form of blood clot.

The move comes after the Nordic country last month stopped using AstraZeneca’s vaccine altogether citing similar concerns.

The country’s health authority said in a statement it had found that “the benefits of using the COVID-19 vaccine from Johnson & Johnson do not outweigh the risk of causing the possible adverse effect in those who receive the vaccine”.

Excluding the J&J vaccine, which accounts for around a third of Denmark‘s total contracted supplies of COVID-19 shots, would delay the country’s vaccination calendar by up to four weeks, it said.

Denmark, which has so far fully vaccinated 11.5% of its population, has gradually been reopening society since early March as infection rates has slowed, including indoor service at restaurants and cafes and allowing football fans into stadiums.

“Taking the present situation in Denmark into account, what we are currently losing in our effort to prevent severe illness from COVID-19 cannot outweigh the risk of causing possible side effects in the form of severe blood clots in those we vaccinate,” the health authority said.

It added that the vaccination rollout is progressing satisfactorily with other available vaccines.

Lawmakers at a meeting on Monday agreed to allow voluntary use of the shots from both Johnson & Johnson and AstraZeneca, lawmaker Liselott Blixt of the Danish People’s Party told Reuters.

The rollout of J&J’s vaccine has also been delayed elsewhere in Europe over similar clotting concerns.

Europe’s drug regulator, the European Medicines Agency, said on April 20 it had found a possible link between J&J’s vaccine and rare blood clotting issues in adults who received doses in the United States.

But it backed the vaccine’s overall benefits against any risks. Since then, several European countries have resumed administering the vaccine.

EMA said its safety committee had concluded that a warning about unusual blood clots with low platelets must be added to the vaccine’s labels, just as was required of AstraZeneca. J&J said in a news release that it would comply with that measure.

Follow the Cyprus Mail on Google News

Related Posts

Authorities warned of ship approach moments before Baltimore bridge collapse

Reuters News Service

Lebanon’s Hezbollah says it launched dozens of rockets after Israeli strikes

Reuters News Service

Trump’s media company surges for second day after stellar debut

Reuters News Service

Migrant crossings to UK hit new record, heaping pressure on Sunak

Reuters News Service

Israeli strikes on Rafah raise fear assault could begin

Reuters News Service

Officials board ship that hit Baltimore bridge, divers search for bodies

Reuters News Service